Physician profile
Ayman S Iskander
NPI 1972599728
$36,719.27
in general payments reported to CMS, 2019-2025
36 companies · $6,054 in 2025
The $6,054 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,482 · 2020: $5,437 · 2021: $6,705 · 2022: $2,860 · 2023: $5,025 · 2024: $6,158 · 2025: $6,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,906 · Consulting Fee: $5,815 · Travel and Lodging: $5,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,905.69 |
| Consulting Fee | $5,815.00 |
| Travel and Lodging | $5,515.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $24,621.20 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic Vascular, INC. | $4,167.48 | 2019-2020 | |
| Inari Medical, INC. | $1,398.43 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $1,086.13 | 2019-2025 | Navitor, Amplatzer Amulet, Diamondback Coronary |
| Boston Scientific Corporation | $831.71 | 2019-2025 | Watchman Flx, Watchman |
| Medtronic, INC. | $794.49 | 2021-2025 | Corevalve Evolut R, Micra, Symplicity G3 |
| Abiomed | $603.02 | 2021-2025 | Impella |
| Amgen INC. | $416.64 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $382.16 | 2019-2023 | Brilinta, Farxiga |
| Penumbra, INC. | $356.34 | 2020-2022 | |
| Thrombolex, INC. | $349.82 | 2023-2025 | Bashir Endovascular Catheter |
| Janssen Pharmaceuticals, INC | $216.58 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.57 | 2019-2025 | Lifevest |
| Pfizer INC. | $175.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $159.84 | 2022-2025 | Verquvo, Capvaxive |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $121.82 | 2019-2025 | Uptravi, Opsumit |
| W. L. Gore & Associates, INC. | $96.19 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $89.52 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $87.53 | 2021-2024 | |
| Biotronik INC. | $76.25 | 2019 | |
| Atricure, INC. | $72.98 | 2020 | |
| Shockwave Medical, INC | $68.81 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.55 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $48.99 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $39.97 | 2020-2021 | |
| Philips North America LLC | $35.35 | 2022-2024 | (Bh4) Igt Devices Undivided |
| Regeneron Healthcare Solutions, INC. | $31.98 | 2021-2023 | Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $29.31 | 2021-2023 | Arcalyst |
| Cardiovascular Systems INC. | $22.65 | 2022 | |
| Angiodynamics, INC. | $19.80 | 2023 | Alphavac |
| Bridgebio Pharma, INC. | $17.93 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $14.43 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.60 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Iskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.